Novel Equation for Estimating Resting Energy Expenditure

October 13, 2020 updated by: Dong Jie, Peking University First Hospital

Novel Equation for Estimating Resting Energy(REE) Expenditure in Chronic Kidney Disease(CKD) 3-5 Stages Patients

The energy and nutrition states are closely associated with CKD patients complications and outcomes.To reach the energy balance target, we need the accurate resting energy expenditure level of patients. Traditional equations are not applicable to CKD patients,so we aim to develop and validate a equation for estimating resting energy expenditure in CKD patients.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100034
        • Renal Division and Institute of Nephrology, Peking University First Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

chronic kidney disease 3-5 stages

Description

Inclusion Criteria:

  • CKD 3-5 stages
  • Age:18-80 years old

Exclusion Criteria:

  • Dialysis and kidney transplantation;
  • Acute complications to hospitalization
  • 1 month prior to the study;
  • Acute or chronic infections, cancer and other wasting diseases in the past year;
  • Thyroid dysfunction;
  • Acute onset of podagra; Musculoskeletal diseases;
  • Respiratory diseases (asthma, pleural effusion, pneumothorax, COPD);
  • History of hormonal drugs use;
  • During pregnancy or lactation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Novel equation development
Time Frame: September 1, 2017 to June 1, 2018
Developed equation for estimating REE in CKD 3-5 stages patients
September 1, 2017 to June 1, 2018
Novel equation validation
Time Frame: June 1, 2018 to March 1, 2019
Validate the noval equation with REE obtained by indirect calorimetry (IC).
June 1, 2018 to March 1, 2019

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking University First Hospital

Investigators

  • Study Director: Jie Dong, Renal Division and Institute of Nephrology, Peking University First Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 14, 2017

Primary Completion (Actual)

January 31, 2020

Study Completion (Actual)

February 1, 2020

Study Registration Dates

First Submitted

December 14, 2017

First Submitted That Met QC Criteria

December 14, 2017

First Posted (Actual)

December 19, 2017

Study Record Updates

Last Update Posted (Actual)

October 14, 2020

Last Update Submitted That Met QC Criteria

October 13, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REE equation

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe